Close

Retinoblastoma

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Overview

Retinoblastoma is a rare form of eye cancer that begins from the multipotential precursor cells of the retina. It is the most common type of malignant eye cancer in children, and 90% of diagnosed cases are children younger than 5 years of age. It may occur in one or both eyes. In the American, approximately 250-500 cases of retinoblastoma are diagnosed each year. Males and females are nearly equally affected and no racial predilection proved to exist. Mutation of genes in chromosomes are the possible causes of some retinoblastoma. The heritable genetic form of retinoblastoma may be related to the mutations of RB1 gene on chromosome 13 while MYCN oncogene amplification may be the cause for some cases of non-hereditary retinoblastoma.

Signs, symptoms and treatments

The most common sign of retinoblastoma is there is a white color in the pupil when light is shone in the eye. Eye redness and swelling, deterioration of vision, strabismus are also signs and symptoms of retinoblastoma. To control the tumor and preserve as much vision as possible, individualized treatment should be used. The treatment usually involves enucleation of the eye, radiotherapy, chemotherapy, laser photocoagulation, thermotherapy and so on. Patients with early medical intervention usually have good prognosis. But the survivors of hereditary retinoblastoma have an increased risk for developing other cancers later in life.

Loading...
Products
Global Services
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.